Wednesday, July 15, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Europe initiates another round of lockdowns

Several European countries have instituted new lockdown restrictions, while others are considering tightening their rules in order to curb the spread of the coronavirus as case numbers across the continent are surging once again.

In France, a new partial lockdown took effect at midnight on Friday. Some 21 million people across 16 regions, including Paris, are affected by the new measures. The French government decided to take the step amid fears of a third wave.

The new lockdown is less restrictive than previous ones. People will be allowed to exercise outdoors and schools will remain open. However, non-essential businesses have been forced to shut down, while others, such as hairdressers, can remain open if they follow strict guidelines.

Source: NPR

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!